These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 8129380)
21. Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureus. Comparison with that of vancomycin. Aoki Y Jpn J Antibiot; 1994 Jun; 47(6):640-6. PubMed ID: 8072172 [TBL] [Abstract][Full Text] [Related]
28. Managing methicillin-resistant staphylococci: a paradigm for preventing nosocomial transmission of resistant organisms. Henderson DK Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S46-54: discussion S64-73. PubMed ID: 16813982 [TBL] [Abstract][Full Text] [Related]
29. [Questionnaires regarding MRSA in Japan]. Hayashi I; Inoue M; Hashimoto H Jpn J Antibiot; 1994 Jun; 47(6):606-17. PubMed ID: 8072168 [TBL] [Abstract][Full Text] [Related]
30. [Drug resistance of methicillin-resistant Staphylococcus aureus (MRSA) in Japan until 1993]. Hashimoto H Jpn J Antibiot; 1994 Jun; 47(6):575-84. PubMed ID: 8072165 [TBL] [Abstract][Full Text] [Related]
31. [An evaluation study on arbekacin for MRSA-infectious diseases including pneumonia, septicemia and others]. Odagiri S; Sumitomo M; Takahashi K; Matsumoto F; Sakurai I; Imai T; Yoshikawa K; Ito A; Sugiyama M; Suzuki M Jpn J Antibiot; 1994 Jun; 47(6):751-62. PubMed ID: 8072184 [TBL] [Abstract][Full Text] [Related]
32. [A study on the resistance of methicillin resistant Staphylococcus aureus to antimicrobial agents]. Wang R; Nishioka K; Tanno Y Zhonghua Nei Ke Za Zhi; 1994 Feb; 33(2):95-8. PubMed ID: 8070299 [TBL] [Abstract][Full Text] [Related]
34. [An attempt to control nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection]. Miyachi N; Ishikawa M; Ohishi F Nihon Rinsho; 1992 May; 50(5):1010-5. PubMed ID: 1507424 [TBL] [Abstract][Full Text] [Related]
35. Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis. Alp E; Gozukucuk S; Canoz O; Kirmaci B; Doganay M BMC Infect Dis; 2004 Oct; 4():43. PubMed ID: 15491501 [TBL] [Abstract][Full Text] [Related]
36. Managing methicillin-resistant staphylococci: a paradigm for preventing nosocomial transmission of resistant organisms. Henderson DK Am J Med; 2006 Jun; 119(6 Suppl 1):S45-52; discussion S62-70. PubMed ID: 16735151 [TBL] [Abstract][Full Text] [Related]
37. [Laboratory and clinical studies on combined effects of fosfomycin plus sulbactam/cefoperazone for mixed infections of MRSA and Pseudomonas aeruginosa]. Hayashi I; Sakurai M; Karato A; Ichiki M; Sekine I; Ishikawa T; Shiotani J; Yoshida T; Niida M; Ogawa M Jpn J Antibiot; 1994 Aug; 47(8):991-1005. PubMed ID: 7933542 [TBL] [Abstract][Full Text] [Related]
38. [The Dutch MRSA policy should be retained]. Vlaminckx BJ; Troelstra A; van der Bruggen T Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1884. PubMed ID: 16970011 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of arbekacin for staphylococcal infection in the NICU. Suzuki K Pediatr Int; 2003 Jun; 45(3):301-6. PubMed ID: 12828585 [TBL] [Abstract][Full Text] [Related]
40. [Clinical studies on vancomycin in the treatment of MRSA infection]. Shimizu K; Orizu M; Kanno H; Kitamura S; Konishi T; Soma K; Nishitani H; Noguchi Y; Hasegawa S; Hasegawa H; Wada K Jpn J Antibiot; 1996 Aug; 49(8):782-99. PubMed ID: 9053533 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]